Influenza is a highly contagious respiratory illness caused by influenza viruses with resultant symptoms which include malaise, fever, headache, tiredness, cough, sore throat, runny or stuffy nose, diarrhea, vomiting and body aches. Diarrhea and vomiting are more common among children than adults. Although most healthy people recover from the influenza without complication, young children, pregnant women, adults over 65 years, people with chronic medical conditions (such as asthma, diabetes, or heart disease), are at a high risk to develop serious complications which include bacterial pneumonia, sinus problems, ear infections, dehydration, and worsening of chronic medical conditions.
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Study Design
Ferrets were anesthetized by injection to reduce expulsion/sneeze during intranasal instillation of 1 mL of viral stock dilution in phosphate buffered saline (PBS). A heating pad is used during the hour of anesthesia to reduce hypothermia.
Viral Stock Quantification Characteristics
The stocks used in these studies remained the same for each exposure-cohort in order to reduce variability. Each stock produces slightly different characteristics; therefore, inoculation reagents are generated in access of forecasted need to ensure additions to studies. Table 1 shows the viral stock quantification characteristics for A/Vietnam/1203/2004 (VN/1203), and Table 2 shows the viral stock quantification characteristics for A/Hong Kong/483/1997 (HK/483). Figure 1 shows a comparison of the viral load by plaque assay and T-5000 Biosensor. 
Results
Decreasing the challenge of VN/1203 increased duration and titer of virus. Neither olfactory bulbs nor brain had culturable virus with the HK/483 challenge. With the VN/1203 challenge, turbinates are positive prior to and/or initially at a higher titer than olfactory bulb and/or brain with both culturable virus and nucleic acid detections.
Quantity and duration of VN/1203 in the brain most likely contributes to morbidity due neurological complications.
Viral Load

Legend Legend
Clinical Sign Onset for VN/1203
Tables 3 and 4 note the timing of onset of signs and not the duration. For example, 12 of 12 animals challenged with 10 2 PFU VN/1203 began having loss of appetite from day 3 to 7. Moribund euthanasias were due to neurological complications for ferrets challenged with VN/1203. Animals challenged with HK/483 were not euthanized due to any clinical sign, but at scheduled times; thus, data for clinical signs have not been included. Figure 2 shows the affected lung histopathology of 10 1 VN/1203. The following histopathology observations were noted. Pneumonia onset presented at 2-3 days post challenge. Moderate to severe meningioencephalitis was observed (onset ~ 4 days post challenge; inflammation observed to day 28). Findings were similar for the 10 2 PFU VN/1203 challenge.
Preliminary IHC
Tissues were stained for HPAI nuclear protein, which were found in the nasal passage, brain, spleen, lymph node, thymus, and liver. Animals were euthanized due to neurological complications more often than for other criteria. In addition to paralysis, weight loss and hypothermia may prove to be significant endpoints for vaccine and therapeutic studies where pneumonic disease causes the moribund state. Figure 3 shows the Kaplan-Meier Curve for VN/1203. 
Conclusions
The ferret model is deemed sufficient to examine human vaccines and treatments for avian influenza. Lower (perhaps more natural transmission) doses predominantly direct a neurological death in the ferret. Brain involvement is likely due to passage of virus from nasal passage to brain rather than from blood to brain. 
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Other neuron
Protection from lower doses of fatal avian influenza may depend on preventing early infection of nasal passages, olfactory bulbs, and the brain.
Future Work
• Determine vaccine efficacy • Provide more evidence for neural/CSF dissemination of VN/1203 Figure 4 shows the proposed viral dissemination route. 
